Healthcare access takes center stage

Access is moving from the margins to the center of healthcare strategy. Regulatory pressure is rising. Expectations are rising. So is scrutiny from investors and governments.

Patients, meanwhile, sit between possibility and reality. Breakthroughs are real. Science moves fast. Yet access still falters in familiar ways: delayed reimbursement, slow diagnostics, uneven coverage, complex referral pathways.

Closing the gap between promise and delivery will not come from incremental adjustments. It requires rethinking how access, pricing, and growth interact.

Equitable access is no longer only a corporate responsibility issue. It is becoming a core commercial design question.

From afterthought to forethought

Pharma is feeling the shift across its traditional strongholds. For decades, the US acted as the key growth engine, with Europe following. Now both face sustained pricing reform and tighter scrutiny. Margins are under pressure. Access is conditional.

As regulators increasingly link market entry to affordability, access reshapes pricing logic. It can no longer be addressed after launch. It must be built in.

Investors are asking sharper questions:

• How is unmet demand being reached?
• How are real-world barriers reflected in launch strategy?
• How do pricing and access plans reinforce each other?

Growth today depends on how therapies perform beyond approval. A product cleared by regulators can still remain out of reach if diagnostics are unavailable, reimbursement is delayed, or supply chains are inconsistent.

Consider a therapy launched with a premium pricing model built for the US. In markets where reimbursement cycles stretch for months and diagnostic capacity is limited, uptake slows. Forecasts are revised. Inventory builds. The science is sound, but the commercial model has not accounted for local access realities.

Designing for access means aligning pricing, evidence, and distribution with how patients actually move through healthcare systems - and not how companies assume they do.

Access does not succeed on goodwill alone. It requires deliberate pricing choices, investment in infrastructure, and clear priorities. If strategy isn’t grounded in how patients actually experience care, growth will stall.

A shift in mindset

Rigid global pricing models are under strain. So are siloed licensing approaches.

An access-first approach requires structured choices:

• Where is evidence generated?
• How are indications sequenced?
• Which affordability mechanisms are viable?
• How is continuity of care ensured?

These decisions affect volume, not just reputation.

Low- and middle-income countries, home to around 80% of the global population, now represent material long-term demand. Health systems are scaling. Insurance coverage is expanding. Infrastructure is improving. Expectations are rising.

Companies that design commercial strategy around these conditions early will capture growth more sustainably than those that treat access as a secondary consideration¹. 

Preparing for the next phase

Growth will increasingly come from removing barriers as much as from launching new products.

That means investing in the practical enablers of uptake: diagnostics that identify patients earlier, education that improves adherence, referral pathways that reduce drop-off, and supply chains that ensure continuity. This is particularly true in rural or underserved areas.

Across markets, access is no longer only about ability to pay. It is about willingness to design commercial models around real constraints. Companies that integrate access into pricing, trial design, and delivery strategy from the outset will unlock demand that others leave unrealized.

In healthcare’s next phase, growth belongs to those who align innovation with how patients actually experience care.